Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Potential role of IFNα in adult lupus
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
2010 (English)In: Arthritis Research & Therapy, ISSN 1478-6354, E-ISSN 1478-6362, Vol. 12, no Suppl 1, p. S3-Article, review/survey (Refereed) Published
Abstract [en]

Patients with lupus have a continuous production of IFNalpha and display an increased expression of IFNalpha-regulated genes. The reason for the ongoing IFNalpha synthesis in these patients seems to be an activation of plasmacytoid dendritic cells (pDCs) by immune complexes (ICs), consisting of autoantibodies in combination with DNA-containing or RNA-containing autoantigens. The mechanisms behind the activation of pDCs by such ICs have to some extent been elucidated during the last years. Thus, interferogenic ICs are internalized via the FcgammaRIIa expressed on pDCs, reach the endosomes and stimulate Toll-like receptor (TLR) 7 or 9, which subsequently leads to IFNalpha gene transcription. Variants of genes involved in both the IFNalpha synthesis and response have been linked to an increased risk to develop lupus. Among these genes are interferon regulatory factor 5 (IRF5), which is involved in TLR signaling, and the signal transducer and activator of transcription 4 (STAT4) that interacts with the type I interferon receptor. Produced IFNalpha may at least partially be responsible for several of the observed alterations in the immune system of lupus patients and contribute to the autoimmune disease process, which will be discussed in the present review. How produced IFNalpha can contribute to some clinical manifestations will briefly be described, as well as the possible consequences of this knowledge in clinical practice for disease monitoring and therapy.

Place, publisher, year, edition, pages
2010. Vol. 12, no Suppl 1, p. S3-
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-126520ISI: 000278012800003PubMedID: 20392290OAI: oai:DiVA.org:uu-126520DiVA, id: diva2:324587
Available from: 2010-06-15 Created: 2010-06-15 Last updated: 2017-12-12Bibliographically approved

Open Access in DiVA

fulltext(249 kB)55 downloads
File information
File name FULLTEXT01.pdfFile size 249 kBChecksum SHA-512
fbb5cf341e10d2cf3bb109fcc37f49ebf6b477f89bb75f058a8fba6af44ddc0b96e9da0fbfb7c33a276d1ca2183b6331163c813e4fa86dc2ffd15f07f3073559
Type fulltextMimetype application/pdf

Other links

PubMedhttp://arthritis-research.com/12/S1/S3

Search in DiVA

By author/editor
Rönnblom, Lars
By organisation
Department of Medical Sciences
In the same journal
Arthritis Research & Therapy
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 55 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 410 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf